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Abstract
In animal experimental models, parasitic helminth infections can protect the host from auto-immune diseases. We
conducted a population-scale human study investigating the relationship between helminth parasitism and auto-reactive
antibodies and the subsequent effect of anti-helminthic treatment on this relationship. Levels of antinuclear antibodies
(ANA) and plasma IL-10 were measured by enzyme linked immunosorbent assay in 613 Zimbabweans (aged 2–86 years)
naturally exposed to the blood fluke Schistosoma haematobium. ANA levels were related to schistosome infection
intensity and systemic IL-10 levels. All participants were offered treatment with the anti-helminthic drug praziquantel and
102 treated schoolchildren (5–16 years) were followed up 6 months post-antihelminthic treatment. ANA levels were
inversely associated with current infection intensity but were independent of host age, sex and HIV status. Furthermore,
after allowing for the confounding effects of schistosome infection intensity, ANA levels were inversely associated with
systemic levels of IL-10. ANA levels increased significantly 6 months after anti-helminthic treatment. Our study shows that
ANA levels are attenuated in helminth-infected humans and that anti-helminthic treatment of helminth-infected people
can significantly increase ANA levels. The implications of these findings are relevant for understanding both the aetiology
of immune disorders mediated by auto-reactive antibodies and in predicting the long-term consequences of large-scale
schistosomiasis control programs.
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Introduction
Three billion people are estimated to be infected with helminths
in tropical and subtropical regions. Several epidemiological studies
have shown an inverse association in the prevalence of helminth
infections and allergy as well as reduced allergic reactivity in
individuals infected with helminth infections [1,2,3,4]. Fewer
studies have been conducted investigating the relationship between
helminth infections and another group of immune disorders, auto-
immune diseases. A global survey published in 2006 showed an
inverse association between the national prevalences of the
intestinal helminth Trichuris trichiura and multiple sclerosis [5].
The inverse relationship between helminth infections and allergy
may therefore extend to auto-immunity, and is likely to have an
immunological basis.
Helminths are thought to manipulate host immune responses to
enhance their survival [6] and, in so doing, dampen immunopa-
thology [7] and reduce host susceptibility to and severity of allergic
[8] and auto-immune diseases [9]. Auto-immune diseases cause
significant and chronic morbidity and disability [10]. Their
epidemiology and aetiology remain poorly understood [10,11],
but experimental studies in mice suggest that infections with
parasitic helminths such as Schistosoma mansoni can protect against
auto-immune diseases including experimental auto-immune en-
cephalomyelitis, the experimental model of multiple sclerosis [12],
Graves hyperthyroidism [13], type 1 diabetes and experimental
colitis [14,15,16].
All currently recognised auto-immune diseases are associated
with circulating auto-reactive antibodies [17] such as anti-nuclear
antibodies (ANA) and they play a central role in the diagnosis and
classification of auto-immune disorders. Auto-reactive antibodies
can appear long before the onset of clinical disease (e.g. anti-
rheumatoid factor auto-reactive antibodies can be detected up to
14 years before the onset of rheumatoid arthritis) and detecting
these antibodies in serum has been shown to have strong
predictive value [11]. Despite such strong association between
auto-reactive antibodies and auto-immune disease, the presence of
auto-reactive antibodies and their role in biological process
remains unclear [18]. Auto-reactive antibodies have been
associated with other conditions including cancer, and acute tissue
damage [18]. Regardless of their function, auto-reactive antibodies
are believed to arise as a result of a breakdown of tolerance
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towards self antigens [18]. They have also been interpreted as
indicators of a generally heightened immune responsiveness, itself
a risk factor for auto-immune disease [19].
We conducted a study to determine the relationship between
the auto-reactive anti-nuclear antibodies (ANA) and parasitic
helminth infection in a human population exposed to Schistosoma
haematobium. This was part of a long term, population-scale study
of schistosome-induced systemic immuno-modulatory effects
which have been suggested to modify immune responses directed
against unrelated antigens such as allergens and self antigens. We
designed a comparative study encompassing two villages with
significantly different schistosome infection levels to determine
if level of helminth endemicity affected the relationship between
ANA levels and schistosome infection. Our previous studies have
shown that different levels of schistosome infection intensity
affect levels of schistosome-specific antibody responses [20] and
experimental studies suggest that the level of helminth-induced
immuno-modulation is affected by helminth infection intensity
[21].
The study also determined the relationship between systemic
IL-10 and ANA level. IL-10 has potent immuno-regulatory and
anti-inflammatory properties (see [22]). In experimental models of
human auto-immune diseases, IL-10 has been shown to mediate
the prevention of autoimmune disease (reviewed in [23]). This has
lead to several clinical trials using both systemically and locally
introduced IL-10 as a therapeutic agent against human auto-
immune diseases such as Crohn’s disease [24].
Finally, the study investigated the effects of removing the
helminth infection with antihelminthic drugs on ANA levels in
school children (the sub-population that is the World Health
Organisation’s recommended target for schistosome control
programmes [25]).
Materials and Methods
Ethical Statement
Permission to conduct the study in the region was obtained from
the Provincial Medical Director and institutional and ethical
approval was received from the University of Zimbabwe’s Institute
Review Board (UZIRB) and the Medical Research Council of
Zimbabwe (MRCZ) respectively. Only compliant participants
were recruited into the study and they were free to drop out at any
point during the study. At the beginning of the study, participants
and their parents/guardians (in case of children) had the aims and
procedures of the project explained fully in the local language,
Shona, and written consent was obtained from participants and
parents/guardian before parasitology and blood samples were
obtained. Participants are involved in an ongoing study on the
effects of helminth infection on regulatory and effector immune
responses. After collection of all samples, all participants were
offered anti-helminthic treatment with the recommended dose of
praziquantel (40 mg/kg of body weight).
Study area
The study was conducted in two villages, Magaya and Chitate, in
the Mashonaland East Province of Zimbabwe (31u909E; 17u639S)
where S. haematobium is endemic. Villagers are subsistence farmers
who have frequent contact with infective water (as assessed by
questionnaires) due to insufficient safe water and sanitation facilities
as is typical in rural Zimbabwe [26,27]. Drinking water is collected
from open wells while bathing and washing is conducted in
perennial rivers surrounding the village. The study area was chosen
for 3 reasons: (1) this area has not been included in the National
Schistosome Control Programme and participants had not received
anti-helminthic treatment for schistosomiasis or other helminth
infections (assessed by questionnaire); (2) similar to most rural areas
in Zimbabwe, there were no reports of soil transmitted helminths
[28,29] and our subsequent parasitological examinations confirmed
this; (3) two villages inhabited by people of similar ethnic groups but
with significantly difference levels of schistosome infection could be
identified in close proximity to allow a comparative study as has
been previously conducted in other areas of Zimbabwe [20]. The
rivers in the two villages differed in their temporal patterns; those in
Magaya are mostly perennial while those in Chitate are seasonal,
leading to different schistosome transmission dynamics.
Plasmodium falciparum is the predominant species of malaria in
Zimbabwe [30] where malaria transmission is largely unstable in
nature and malaria transmission in the study area is classified as
low and sporadic [31,32,33] with an annual incidence of malaria
of 1-10 cases/1000 people in the area [33,34].
Parasitology
Stool and urine specimens were collected on three consecutive
days and these were examined for S. haematobium, S. mansoni and
geo-helminths using standard procedures. Briefly, urine specimens
were processed by urine filtration following a standard method
originally described by Mott et al. for diagnosis of S. haematobium
[35]. Fresh stool specimens were processed by the Kato-Katz [36]
technique and subsequently analysed by microscopy for intestinal
helminths including S. mansoni, hookworm, Ascaris lumbricoides and
Trichuris trichiura. The formol-ether concentration method was
performed on a random sample of 25% of the samples to confirm
results obtained by the Kato-Katz technique. After collection of all
samples, all participants were offered anti-helminthic treatment
with the recommended dose of praziquantel (40 mg/kg of body
weight). There were no untreated controls for this study because
the high levels of infection meant all compliant participants were
treated as recommended by the World Health Organization’s
Guidelines.
Study participants: inclusion/exclusion criteria
In order to be included in the study, participants had to meet
all the following criteria: 1) have provided at least two (to allow
calculation of a mean infection intensity) urine and two stool
samples on consecutive days; 2) be negative for intestinal
helminths including S. mansoni (no one was excluded on this
criteria as everyone was negative for these infections); and 3) have
given a blood sample for the collection of sera. A total 613
participants aged 2–86 years met these criteria and formed our
study population. Of these, 369 (2–86 years old) were recruited
from Chitate (low schistosome infection area) and 244 (4–86 years
old) from Magaya (high schistosome infection area). Of these, 602
people gave enough sera to allow the additional IL-10 serological
assay. To be included in the follow-up post-treatment study,
treated participants had to: 1) be school-enrolled children (the
target population for mass chemotherapy [25]) from Magaya, the
high infection area, (to ensure that children with high infection
levels were captured in the study) enrolled in the cross sectional
study; 2) have been confirmed egg negative for schistosome
infections 6 weeks post anti-helminthic treatment (no one was
excluded on this basis as all children receiving ant-helminthic
treatment were successfully cured of their schistosome infection);
and 3) have given a blood sample for sera collection 6 months
after anti-helminthic treatment (5 children were excluded on this
criteria). 102 participants (5–16 years old) from Magaya were
included based on these criteria.
Helminth Infection and Anti-Nuclear Antibodies
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Laboratory assays
Auto-immune reactivity was assessed by measuring serum
antibodies directed against nuclear antigens (ANA) including
RNP, Sm, SSA, SSB, Scl-70, Jo-1, CENP-B, Ribosomal P, DNA
and histones using a routine diagnostic ELISA kit for the detection
of disease-specific anti-nuclear antibodies (REAADS ANA Test
Kit, Cat 10876) in a single ELISA. According to the manufac-
turer’s product sheet, when the kit was tested with sera from
patients suffering from Systemic Lupus Erythematosus, Sjo¨gren’s
Syndrome, Systemic Sclerosis and, it had a sensitivity greater than
94% for these syndromes and 95% specificity. The level of auto-
immune reactivity (Units/ml (U/ml)) was calculated using
negative, positive and calibrator control samples supplied by the
manufacturer. HIV status was determined using the USAID-
approved HIV1+2 Double Check Gold rapid serological tests
(Orgenics). Positive HIV status was confirmed by a second assay
using a different rapid test, Determine HIV 1/2 Ag/Ab Combo.
Systemic IL-10 levels were measured by ELISA using a kit from
BD Biosciences (Cat 555157) following manufacturer instructions.
Participants were screened for malaria both by microscopic
examination of Giemsa stained blood smears as well as by a
rapid serological assay (Paracheck Pf (P. falciparum) Rapid Test
(Dipstick) supplied by Orchid Biomedical Systems.
Statistical analyses
Statistical analyses were conducted using the statistical package
SPSS. The difference in schistosome infection level between the
two villages was determined by x-squared test (prevalence) and
analysis of variance (ANOVA) (mean infection intensity, (log X +1)
transformed). The relationship between the levels of anti-nuclear
antibodies ((ANA) and schistosome infection intensity before anti-
helminthic treatment was determined using an ANOVA. The
dependent variable was ANA level. Infection intensity categorised
into 3 groups according to the severity of infection as classified by
the World Health Organisation [25] as no infection (0 eggs/10 ml
urine), low-mild infection (1–49 eggs/10 ml urine) and high/heavy
infection (50 or more eggs/10 ml urine), sex (2 categories: male,
female), village (2 categories: low infection area, high infection
area), age group (3 age groups: 1 (2–10 years), 2 (11–20 years) and
3(21+ years) reflecting age groups where infection is rising, peaking
and declining respectively) and HIV status (2 categories: positive,
negative) were the independent variables. Age and schistosome
infection intensity was categorised to satisfy the assumptions of
parametric tests (see [37]). The age groups reflected the ages were
schistosome infection was rising, peaking and declining. Sequential
sums of squares were used with schistosome infection intensity
entered last in the model to allow for the effects of all the other
variables before testing for its effects.
The levels of systemic IL-10 between the two villages was
compared by an ANOVA allowing for the effects of host sex, age
group and schistosome infection level categorised as above. Our
previous studies in villages in the same province have shown that
systemic levels of IL-10 can vary with host age and schistosome
infection levels [38]. Therefore, to avoid the confounding effects of
host age and infection intensity on the relationship between IL-10
and ANA levels, the variation in ANA levels due to host age and
infection intensity was allowed for first, in an ANOVA, together
with the effects of sex, village and HIV categories as above, before
determining if there was a significant association between IL-10
levels (square root transformed) and ANA levels. The effect of anti-
helminthic treatment on auto-reactive antibody and on IL-10
levels was tested using a repeated measure ANOVA with age, sex
and schistosome infection intensity.
Results
Levels of schistosome infection and ANA antibodies
differ between the two villages
We first established that the two study locations differed in levels
of endemic schistosome infection. Schistosome infection prevalence
was significantly higher in Magaya (prevalence = 69%, 95% CI:
63% to 75%) than in Chitate (prevalence = 14%, 95% CI: 11% to
18%) (x2 = 187, df = 1, p,0.001), as was infection intensity 58 eggs/
10 ml urine (Standard error of the mean (SEM) = 8.02) and 15
eggs/10 ml urine (SEM =4.17) respectively (F1, 612= 201,
p,0.001). Infection levels followed the typical age-infection pattern
originally described for schistosome infections with infection rising
with age to peak in childhood/early adulthood before declining as
shown in Figure 1. Levels of infection differed significantly between
the two villages in the two younger age groups (ages 2–20years old)
but were comparable in the oldest age group (21 years and above).
Furthermore, the effect of interaction between age group and village
of residence on schistosome infection intensities was significant
(F2,612 = 8.96, p,0.001), indicating the phenomenon known as
‘peak shift’ [39], where peak infection levels are higher and occur
earlier in areas of high schistosome transmission compared to low
schistosome transmission areas. Given the significant differences in
schistosome infection level in the two villages, we determined if
mean ANA levels differed between the two villages. This was the
case (F1,612 = 57,6 p,0.001) with the mean ANA level of 22.6 U/ml
(SEM=1.13) in Chitate, the low infection area, being significantly
higher than the ANA level of 17 U/ml (SEM=1.30) inMagaya, the
high infection area.
When the two study populations were partitioned by the levels
of schistosome infection recommended by WHO (Table 1), there
were no significant differences in the mean infection intensity in
the uninfected category (0 egg/10 ml urine) and in the heavy
infection category (50+ eggs/10 ml urine). However, in the low-
mild infection category (1–49 eggs/10 ml urine), mean infection
intensity was higher in the high infection area compared to the low
infection area (mean of 18 eggs vs. 15eggs/10 ml urine,
Figure 1. Distribution of schistosome infection intensity with
age in the study villages: Mean infection intensity is higher in
Magaya Village, high schistosome infection area (black) compared to
Chitate Village, low schistosome infection area (white). Bars represent
standard error of the mean.
doi:10.1371/journal.pone.0019149.g001
Helminth Infection and Anti-Nuclear Antibodies
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F1, 145 = 5,4, p,=0.022). ANA levels are shown for each infection
group for the two villages in Figure 2.
Anti-nuclear antibody levels are inversely related to
schistosome infection intensity in the individuals
We tested for the relationship between ANA level and
schistosome infection intensity. After allowing for the variation
due to age group, sex, HIV status and place of residence, the
analysis showed that levels of ANA in the two villages were
inversely related to individuals’ schistosome infection level
(F1,612 = 4.3, p,0.05), with significant differences occurring
between people with no infection or low-medium infection and
those carrying heavy infections (Figure 3). This analysis also
showed that participant age (divided into 3 age groups) did not
have a significant effect on ANA levels (F2,612 = 0.49, p = 0.61),
Figure 4 and neither did HIV status (F1,612 = 2.9, p = 0.09) nor
participant sex (F1,612 = 1.22, p = 0.26).
Anti-nuclear antibody levels increase following
anti-helminthic treatment
To address the question of whether schistosome infection may
be causing a reduction of ANA levels in infected subjects, we
examined a cohort of 102 school children aged 5–16 years of age
from the high infection area, Magaya, 6 months following
treatment with the anti-helminthic praziquantel to remove adult
schistosome parasites. Before treatment schistosome infection
prevalence was 75% amongst these children (77/102) and
infection ranged from 0–800 eggs/10 ml urine with a mean of
62 eggs/10 ml urine and SEM of 12,36. The treatment efficacy
check at six weeks post-treatment showed that all 102 were egg
Table 1. Description of study populations’ infection levels.
Residential area WHO Infection code Sample size
Mean schistosome infection
intensity
Standard error of the
mean
High infection area None 76 0 0.00
Low-Medium 115 18 1.23
High 53 226 26.03
Total 244 58 8.02
Low infection area None 316 0 0.00
Low-Medium 31 10 1.72
High 22 242 49.51
Total 369 15 4.15
Total study population None 392 0 0.00
Low-Medium 146 16 1.07
High 75 230 23.26
Total 613 32 4.13
Table shows sample sizes of the number of people in each infection level in the two areas. The infection levels are based on WHO classification of Schistosoma
haematobium infection into no infection (0eggs/10 ml urine), low-medium infection (1–49 eggs/10 ml urine) and heavy infection (50+ eggs/10 ml urine) [25].
doi:10.1371/journal.pone.0019149.t001
Figure 2. Levels of anti-nuclear antibody (ANA) levels in the
different infection groups in the study villages. Bars represent
individuals carrying no infection in black, low-mild infection intensity
(1–49 eggs/10 ml urine) in grey and high infection intensity (50+ eggs/
10 ml urine) in white. S. haematobium infection intensity was quantified
by urine filtration. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0019149.g002
Figure 3. Relationship between anti-nuclear antibody (ANA)
and schistosome infection levels. Bars represent residual variation
in ANA levels after allowing for the variation due to host sex, age group,
HIV status and village.
doi:10.1371/journal.pone.0019149.g003
Helminth Infection and Anti-Nuclear Antibodies
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negative for schistosome infection. By six months after treatment
just 11 of the children had become re-infected with schistosomes,
and with only low intensities of infection (range from 0–48 eggs/
10 ml urine with a mean of 1 egg/10 ml urine and SEM of 0.50.
Furthermore, at the six month post-treatment time point, auto-
reactive antibody levels had risen significantly (F1, 99 = 15. 85,
p,0.001) as shown in Figure 5.
Anti-nuclear antibody levels are inversely related to
systemic IL-10 levels
Systemic IL-10 levels in Chitate were less than those in Magaya
at 0.802 ng/ml (SEM 0.073) compared to 1.07 ng/ml
(SEM=0.049), this difference was statistically significant
(F1,602 = 50.0, p,0.001) after allowing for host age, sex, age
group, ANA level and schistosome infection level. In both villages
schistosome infection was negatively associated with IL-10 levels
(Chitate F2,365 = 5.12, p= 0.006; Magaya F2, 237 = 2.70, p = 0.069).
In the high infection area the relationship between infection level
and schistosome infection changed with host age (F2, 237 = 6.34,
p = 0.002) which was not the case in the low infection are
(F2, 365 = 2.84 p= 0.06). Furthermore, ANA levels were inversely
associated with IL-10 levels (F1,602 = 10.3, p= 0.01) after allowing
for the effects of residential area, host age, sex, age group and
schistosome infection level as shown in Figure 6. Following
treatment, 78 of the 102 children gave enough serum to also
measure systemic IL-10 levels, and analyses of these results showed
that IL-10 levels rose significantly following treatment (F1,74 = 200,
p,0.001).
Discussion
This study investigated the distribution of anti-nuclear antibod-
ies in human populations naturally exposed to a helminth
infection. Our results showed that ANA levels were significantly
lower in a population exposed to higher levels of S. haematobium
infection compared to a population exposed to lower levels.
Moreover, within those populations ANA levels were negatively
correlated with schistosome infection level. This relationship was
robust to potential confounders, host age, sex, HIV status and
residential location. In school-aged children, ANA levels increased
following curative anti-helminthic treatment with praziquantel.
None of the participants in this study were positive for malaria
infection (both by microscopic examination of blood smear or
serological detection of Plasmodium falciparum antigens); therefore
ANA levels in these populations cannot be attributed to malaria
infection as has been reported in other settings [40]. However,
there are several possible explanations for an association between
infectious agents and ANA levels. First, the molecular mimicry
hypothesis has been suggested to explain a relationship between
some pathogens and ANA levels as well as auto-immune reactivity,
i.e. antigenic determinants of micro-organisms may resemble
antigenic determinants of their host, and so elicit an auto-immune
response that harms the host [41]. The prediction of this
hypothesis would be a positive association between schistosome
infection and ANA levels which contradicts the observation in this
study. Furthermore, removal of the pathogen by treatment would
not lead to an increase in ANA levels. Second, the drug
praziquantel could, in theory, increase auto-reactive antibody
levels. Some drugs can induce auto-reactive antibodies which
would subsequently disappear after stopping drug therapy [42].
However, there have not been any reports of praziquantel
inducing ANA and, furthermore, drug induced auto-reactivity
Figure 4. Relationship between anti-nuclear antibody (ANA)
levels and host age in the study villages. Error bars represent
standard error of the mean.
doi:10.1371/journal.pone.0019149.g004
Figure 5. Effect of antihelminthic treatment on anti-nuclear
antibody (ANA) levels. Increase in of ANA levels in school children
from the high schistosome infection area, Magaya six months after anti-
helminthic treatment with praziquantel.
doi:10.1371/journal.pone.0019149.g005
Figure 6. Relationship between anti-nuclear antibody (ANA
level) and systemic IL-10 levels. The relationship between ANA
(residual variation in ANA levels after allowing for the variation due to
host sex, age group, HIV status and village) and IL-10 levels (square root
transformed). P value is derived from ANOVA.
doi:10.1371/journal.pone.0019149.g006
Helminth Infection and Anti-Nuclear Antibodies
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would not explain the inverse association between ANA and
schistosome infection level before treatment, since all participants
had no prior history of anti-helminthic treatment. Third, ANA
could be protective against schistosome infection, so that the ANA
production preceded exposure to infection and provided protec-
tion against infection. This explanation has been proposed in
malaria infections (reviewed in [43]) where cross-reactivity occurs
between human and Plasmodium falciparum antigens and correlates
with clinical protection against malaria [44]. While this hypothesis
might explain the negative association between schistosome
infection and ANA levels, it again, does not explain the rise in
ANA levels following anti-helminthic treatment. Furthermore, it
does not explain the difference in ANA levels between the two
areas (both populated by the same ethnic group) with different
levels of schistosome infection in the two populations.
We consider that the best explanation for the negative
association between schistosome infection and ANA levels
observed in our study is the so-called ‘hygiene hypothesis’ first
proposed by Strachan in 1989 [45]. The hypothesis suggests that
exposure to infectious agents, such as parasitic helminths, elicits
immune deviation or dampening that serves to reduce incidence
or severity of allergy [8] and auto-immune reactivity [9]. This may
result from the need for helminths to manipulate host immune
responses to enhance their survival [7]. One prediction from this
hypothesis is that schistosome infection levels will be inversely
associated with ANA levels. Furthermore, in keeping with results
from experimental allergy studies [21], the higher the overall
schistosome infection level, the lower the expected level of ANA
reactivity in the population. This hypothesis would also predict
that removing the schistosome worms would result in an increase
in ANA levels. Our results are consistent with all these predictions.
To date, there are no published studies on the effects of anti-
helminth treatment on ANA levels in human or experimental
studies. The increase in ANA levels we report is consistent with
reports from the allergy studies which show an increase in atopic
reactivity following anti-helminthic treatment [46].
Our demonstration that systemic IL-10 levels were significantly
higher in Magaya (the high infection areas) and that they were
inversely related to auto-reactive antibody levels in both villages is
consistent with IL-10 being associated with immuno-modulation
of host responses.[22]. The overall increase in systemic IL-10 levels
following treatment may be related to an increase in schistosome-
specific IL-10, as has been reported in human S. mansoni infections
[47]. A possible explanation for this increase may be that the
parasite antigens presented to the immune system as a result of
dying schistosome worms may induce an increase in IL-10 levels.
Our results show a clear relationship between schistosome
infection levels and ANA levels auto-reactive antibody levels. ANA
levels were reduced in helminth-infected humans and anti-
helminth treatment of helminth-infected people resulted in a
significant increase in ANA levels. The results indicate the need for
further investigation into the nature and aetiology of the
association between helminth infections and ANA. Furthermore,
there is need for further studies on the implications of high ANA
levels in terms of the development of pathology. The use of
population-based studies with different levels of helminth ende-
micity such as ours, complemented by experimental mechanistic
studies in animal models will clarify the relationship between the
epidemiology/aetiology of immune disorders and different hel-
minth groups pre- and post anti-helminth treatment. Our study
adds to the growing studies characterising the short-term and long-
term effects of antihelminthic treatment [48] in the face of current
large scale global helminth control initiatives whose long-term
health consequences have yet to be fully understood.
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